Obagi Medical has announced significant new clinical data regarding its hyaluronic acid injectables and Nu-Cil scalp treatment, presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting held from November 13 to 16, 2025, in Chicago, Illinois. This data highlights the effectiveness of Obagi’s hyaluronic acid fillers in midface augmentation and their positive impact on the appearance of nasolabial folds.
The pivotal study, which compared two hyaluronic acid fillers, was recognized as one of the top ten abstracts at the conference, presented by Dr. Sue Ellen Cox. This recognition underscores the growing interest in innovative treatments within the dermatological field and positions Obagi Medical at the forefront of aesthetic solutions.
Impact of New Clinical Findings
The clinical findings presented at the ASDS meeting illustrate how Obagi hyaluronic acid fillers can enhance facial volume and improve the appearance of wrinkles. The study involved a comprehensive analysis of patient outcomes following treatment with these injectables. The results indicated a notable improvement in both patient satisfaction and aesthetic results, reinforcing the importance of advanced hyaluronic acid formulations in cosmetic dermatology.
Obagi Medical’s commitment to research and development is evident in this latest study, which aligns with its mission to provide effective physician-dispensed skincare solutions. The company continues to explore innovative products that meet the evolving needs of patients seeking aesthetic enhancements.
About Obagi Medical and Waldencast plc
Obagi Medical is recognized as a leader in the field of skincare and aesthetic solutions. As a subsidiary of Waldencast plc (NASDAQ: WALD), the company benefits from a robust framework that supports its research initiatives and product development. Waldencast plc is committed to expanding its portfolio of innovative healthcare brands, making quality skincare accessible to a wider audience.
The ASDS Annual Meeting serves as a key platform for dermatology professionals to share research findings and discuss advancements in the field. With presentations from leading experts like Dr. Cox, the event fosters collaboration and encourages the sharing of knowledge that can enhance patient care.
As Obagi Medical continues to disseminate its findings and develop new products, the impact of its research extends beyond the conference, influencing practitioners and patients alike in their approach to skincare and aesthetic treatments. The positive outcomes from this recent study may lead to increased adoption of Obagi’s products in clinical settings, further solidifying the company’s reputation as a trusted name in skincare innovation.
